{"filing":{"accession_number":"0001104659-26-095425","cik":"0001612940","ticker":"PRQR","company_name":"ProQR Therapeutics N.V.","form":"6-K","filing_date":"2026-08-13","report_date":"2026-06-30","primary_document":"prqr-20260630x6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1612940/000110465926095425/prqr-20260630x6k.htm"},"events":[{"id":27452,"run_id":25028,"accession_number":"0001104659-26-095425","anchor_item_number":"EX-99.2","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This exhibit is a press release announcing ProQR's second quarter 2026 operating and financial results, including Q2 net loss of €8.7 million, cash position of €117.1 million, and key clinical milestones (AX-0810 Phase 1 target engagement data, AX-0811 CTA submission, financing of $59.2 million). The document explicitly states \"ProQR Therapeutics N.V. (Nasdaq: PRQR)...today reported its financial and operating results for the second quarter ended June 30, 2026\" and includes unaudited interim condensed consolidated financial statements (balance sheet, income statement, changes in equity). This is a discrete earnings announcement, not a periodic financial report filing.","company_name":"ProQR Therapeutics N.V.","ticker":"PRQR","filing_date":"2026-08-13","form":"6-K","submitted_at":null,"items":[{"id":29007,"accession_number":"0001104659-26-095425","item_number":"EX-99.2","item_title":"prqr-20260630xex99d2.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a press release announcing ProQR's second quarter 2026 operating and financial results, including Q2 net loss of €8.7 million, cash position of €117.1 million, and key clinical milestones (AX-0810 Phase 1 target engagement data, AX-0811 CTA submission, financing of $59.2 million). The document explicitly states \"ProQR Therapeutics N.V. (Nasdaq: PRQR)...today reported its financial and operating results for the second quarter ended June 30, 2026\" and includes unaudited interim condensed consolidated financial statements (balance sheet, income statement, changes in equity). This is a discrete earnings announcement, not a periodic financial report filing.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:02:35.251375+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29006,"accession_number":"0001104659-26-095425","item_number":"EX-99.1","item_title":"prqr-20260630xex99d1.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is ProQR's unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2026, prepared in accordance with IAS 34 Interim Financial Statements. The document presents a complete set of interim financial statements (statement of financial position, profit or loss, changes in equity, and cash flows) with comparative periods, along with explanatory notes. This is a periodic interim financial report, not a discrete event or earnings release announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:02:35.251375+00:00","company_name":"ProQR Therapeutics N.V.","ticker":"PRQR","filing_date":"2026-08-13"},{"id":29007,"accession_number":"0001104659-26-095425","item_number":"EX-99.2","item_title":"prqr-20260630xex99d2.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a press release announcing ProQR's second quarter 2026 operating and financial results, including Q2 net loss of €8.7 million, cash position of €117.1 million, and key clinical milestones (AX-0810 Phase 1 target engagement data, AX-0811 CTA submission, financing of $59.2 million). The document explicitly states \"ProQR Therapeutics N.V. (Nasdaq: PRQR)...today reported its financial and operating results for the second quarter ended June 30, 2026\" and includes unaudited interim condensed consolidated financial statements (balance sheet, income statement, changes in equity). This is a discrete earnings announcement, not a periodic financial report filing.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:02:35.251375+00:00","company_name":"ProQR Therapeutics N.V.","ticker":"PRQR","filing_date":"2026-08-13"}]}